Phibro director buys 10,000 shares in open market

PHIBRO ANIMAL HEALTH CORP director E. Thomas Corcoran bought 10,000 shares of Class A Common Stock in an open-market purchase.

Rhea-AI Filing Summary

PHIBRO ANIMAL HEALTH CORP director E. Thomas Corcoran bought 10,000 shares of Class A Common Stock in an open-market purchase. The weighted average price was $31.77 per share, with trade prices ranging from $31.66 to $31.85.

After this transaction, he directly holds 41,459 shares, which includes 1,459 shares acquired through a dividend reinvestment plan sponsored by his broker.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider CORCORAN E THOMAS

Role Director

Bought 10,000 shs ($318K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	10,000	$31.77	$318K

Holdings After Transaction: Class A Common Stock — 41,459 shares (Direct)

Footnotes (2)

1. F1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.66 to $31.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.
2. F2. Includes 1,459 shares acquired under a dividend reinvestment plan sponsored by the Reporting Person's broker.

Key Figures

Shares purchased: 10,000 shares Weighted average price: $31.77 per share Trade price range: $31.66–$31.85 per share +2 more

5 metrics

Shares purchased 10,000 shares Open-market purchase of Class A Common Stock

Weighted average price $31.77 per share Price for 10,000-share open-market purchase

Trade price range $31.66–$31.85 per share Range of individual trade prices on purchase date

Holdings after transaction 41,459 shares Director’s direct ownership following the purchase

Dividend reinvestment plan shares 1,459 shares Portion of holdings from broker dividend reinvestment plan

Key Terms

open-market purchase, weighted average price, dividend reinvestment plan

3 terms

open-market purchase financial

"reported an open-market purchase of 10,000 shares of Phibro Animal Health"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported is a weighted average price. These shares were purchased"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

dividend reinvestment plan financial

"Includes 1,459 shares acquired under a dividend reinvestment plan sponsored"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Phibro Animal Health (PAHC) director E. Thomas Corcoran do in this Form 4?

Director E. Thomas Corcoran reported an open-market purchase of 10,000 shares of Phibro Animal Health Class A Common Stock. This transaction increases his direct ownership stake disclosed in the filing and reflects a cash investment at current market prices.

At what price did the PAHC director buy the 10,000 shares of stock?

The shares were bought at a weighted average price of $31.77 per share. Individual trades occurred in a price range from $31.66 to $31.85, as disclosed, with full trade-by-trade details available upon request from the parties listed.

How many Phibro Animal Health shares does the director own after this transaction?

After the reported purchase, the director directly owns 41,459 shares of Phibro Animal Health Class A Common Stock. This total includes 1,459 shares that were previously acquired through a dividend reinvestment plan managed by his broker.

What does the dividend reinvestment plan reference mean in the PAHC Form 4?

The filing notes that 1,459 of the director’s shares were acquired under a broker-sponsored dividend reinvestment plan. In such plans, cash dividends are automatically used to buy additional shares instead of being paid out in cash to the shareholder.

Was this PAHC insider transaction a buy or a sell?

This insider transaction was a buy, specifically an open-market purchase coded as “P” on the Form 4. The director acquired 10,000 additional shares, and there were no reported sales or derivative exercises in the same filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 06:56 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CORCORAN E THOMAS

(Last) (First) (Middle)

300 FRANK W. BURR BLVD.,

STE. 21

(Street)

TEANECK NEW JERSEY 07666

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/29/2026		P		10,000	A	$31.77(1)	41,459(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.66 to $31.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range.

2. Includes 1,459 shares acquired under a dividend reinvestment plan sponsored by the Reporting Person's broker.

	/s/ Judith Weinstein, as Attorney-in-Fact for E. Thomas Corcoran	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)